Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026)
Galectin Therapeutics' quarterly Share-based Compensation came in at $686000.0 in Q1 2026, up 46.58% year-on-year from $468000.0 in Q1 2025, and up 257.29% quarter-over-quarter from $192000.0 in Q4 2025.
Galectin Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $686000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 46.58% year-over-year to $686000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 33.62% YoY), and the FY2025 full-year result was $1.7 million, down 32.33% from the prior year.
- Share-based Compensation for Q1 2026 stood at $686000.0, up from $192000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.1 million in Q4 2024, with the low at $192000.0 in Q4 2025.
- Average Share-based Compensation over 5 years is $613764.7, with a median of $604000.0 recorded in 2024.
- Year-over-year, Share-based Compensation surged 2351.43% in 2022 and tumbled 82.62% in 2025.
- Tracing GALT's Share-based Compensation over 5 years: stood at $681000.0 in 2022, then declined by 27.02% to $497000.0 in 2023, then surged by 122.33% to $1.1 million in 2024, then plunged by 82.62% to $192000.0 in 2025, then surged by 257.29% to $686000.0 in 2026.
- The last three Share-based Compensation figures came in at $686000.0 (Q1 2026), $192000.0 (Q4 2025), and $498000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 686,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 686,000.00 |
| Mar 31, 2026 | 686,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 1.11 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 515,000.00 |
| Sep 30, 2024 | 515,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Mar 31, 2024 | 604,000.00 |
| Mar 31, 2024 | 604,000.00 |
| Dec 31, 2023 | 405,000.00 |
| Dec 31, 2023 | 405,000.00 |
| Sep 30, 2023 | 586,000.00 |
| Sep 30, 2023 | 586,000.00 |
| Jun 30, 2023 | 516,000.00 |
| Jun 30, 2023 | 516,000.00 |
| Mar 31, 2023 | 662,000.00 |
| Mar 31, 2023 | 662,000.00 |
| Dec 31, 2022 | 681,000.00 |
| Dec 31, 2022 | 681,000.00 |
| Sep 30, 2022 | 681,000.00 |
| Sep 30, 2022 | 681,000.00 |
| Jun 30, 2022 | 647,000.00 |
| Jun 30, 2022 | 647,000.00 |
| Mar 31, 2022 | 858,000.00 |
| Mar 31, 2022 | 858,000.00 |
| Dec 31, 2021 | 654,000.00 |
| Dec 31, 2021 | 654,000.00 |
| Sep 30, 2021 | 587,000.00 |
| Sep 30, 2021 | 587,000.00 |
| Jun 30, 2021 | 581,000.00 |
| Jun 30, 2021 | 581,000.00 |
| Mar 31, 2021 | 35,000.00 |
| Mar 31, 2021 | 35,000.00 |
| Dec 31, 2020 | 567,000.00 |
| Dec 31, 2020 | 567,000.00 |
| Sep 30, 2020 | 408,000.00 |
| Sep 30, 2020 | 408,000.00 |
| Jun 30, 2020 | 394,000.00 |
| Jun 30, 2020 | 394,000.00 |
| Mar 31, 2020 | 430,000.00 |
| Mar 31, 2020 | 430,000.00 |
| Dec 31, 2019 | 414,000.00 |
| Dec 31, 2019 | 414,000.00 |
| Sep 30, 2019 | 414,000.00 |
| Sep 30, 2019 | 414,000.00 |
| Jun 30, 2019 | 443,000.00 |
| Jun 30, 2019 | 443,000.00 |
| Mar 31, 2019 | 412,000.00 |
| Mar 31, 2019 | 412,000.00 |
| Dec 31, 2018 | 4.43 Mn |
| Dec 31, 2018 | 4.43 Mn |
| Sep 30, 2018 | 1,000.00 |
| Sep 30, 2018 | 1,000.00 |
| Jun 30, 2018 | 1.44 Mn |
| Jun 30, 2018 | 1.44 Mn |
| Mar 31, 2018 | 7,000.00 |
| Mar 31, 2018 | 7,000.00 |
| Dec 31, 2017 | 6,000.00 |
| Dec 31, 2017 | 6,000.00 |
| Sep 30, 2017 | 230,000.00 |
| Sep 30, 2017 | 230,000.00 |
| Jun 30, 2017 | 269,000.00 |
| Jun 30, 2017 | 269,000.00 |
| Mar 31, 2017 | 14,000.00 |
| Mar 31, 2017 | 14,000.00 |
| Dec 31, 2016 | 478,000.00 |
| Dec 31, 2016 | 478,000.00 |
| Sep 30, 2016 | 376,000.00 |
| Sep 30, 2016 | 376,000.00 |
| Jun 30, 2016 | 402,000.00 |
| Jun 30, 2016 | 402,000.00 |
| Mar 31, 2016 | 1.22 Mn |
| Mar 31, 2016 | 1.22 Mn |
| Dec 31, 2015 | 71,000.00 |
| Dec 31, 2015 | 71,000.00 |
| Sep 30, 2015 | 793,000.00 |
| Sep 30, 2015 | 793,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Mar 31, 2015 | 935,000.00 |
| Mar 31, 2015 | 935,000.00 |
| Dec 31, 2014 | 799,000.00 |
| Dec 31, 2014 | 799,000.00 |
| Sep 30, 2014 | 877,000.00 |
| Sep 30, 2014 | 877,000.00 |
| Jun 30, 2014 | 745,000.00 |
| Jun 30, 2014 | 745,000.00 |
| Mar 31, 2014 | 25,000.00 |
| Mar 31, 2014 | 25,000.00 |
| Dec 31, 2013 | 513,000.00 |
| Dec 31, 2013 | 513,000.00 |
| Sep 30, 2013 | 1.81 Mn |
| Sep 30, 2013 | 1.81 Mn |
| Jun 30, 2013 | 173,000.00 |
| Jun 30, 2013 | 173,000.00 |
| Mar 31, 2013 | 852,000.00 |
| Mar 31, 2013 | 852,000.00 |
| Dec 31, 2012 | 622,000.00 |
| Dec 31, 2012 | 622,000.00 |
| Sep 30, 2012 | 819,000.00 |
| Sep 30, 2012 | 819,000.00 |
| Jun 30, 2012 | 879,000.00 |
| Jun 30, 2012 | 879,000.00 |
| Mar 31, 2012 | 473,000.00 |
| Mar 31, 2012 | 473,000.00 |
| Dec 31, 2011 | -2.58 Mn |
| Dec 31, 2011 | -2.58 Mn |
| Sep 30, 2011 | 649,000.00 |
| Sep 30, 2011 | 649,000.00 |
| Jun 30, 2011 | 1.33 Mn |
| Jun 30, 2011 | 1.33 Mn |
| Mar 31, 2011 | 711,000.00 |
| Mar 31, 2011 | 711,000.00 |
| Dec 31, 2010 | -1.44 Mn |
| Dec 31, 2010 | -1.44 Mn |
| Sep 30, 2010 | 404,000.00 |
| Sep 30, 2010 | 404,000.00 |